Generate Investment Management Ltd Raises Stock Position in Eli Lilly and Company $LLY

Generate Investment Management Ltd raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 172.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 66,461 shares of the company’s stock after purchasing an additional 42,083 shares during the period. Eli Lilly and Company accounts for approximately 2.9% of Generate Investment Management Ltd’s holdings, making the stock its 7th biggest position. Generate Investment Management Ltd’s holdings in Eli Lilly and Company were worth $51,808,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. WestEnd Advisors LLC boosted its position in Eli Lilly and Company by 210.0% during the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after acquiring an additional 21 shares during the period. Wealth Preservation Advisors LLC bought a new stake in shares of Eli Lilly and Company during the first quarter valued at about $27,000. Citizens National Bank Trust Department raised its stake in shares of Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company in the first quarter worth about $40,000. Finally, TD Capital Management LLC grew its position in Eli Lilly and Company by 129.2% in the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after buying an additional 31 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on LLY shares. Leerink Partners restated a “market perform” rating and set a $715.00 price target on shares of Eli Lilly and Company in a research report on Thursday, August 7th. JPMorgan Chase & Co. lowered their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, September 16th. Wall Street Zen lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday, September 20th. DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 14th. Finally, Erste Group Bank lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a research note on Thursday, June 5th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $939.61.

Insider Activity

In other news, Director Jamere Jackson purchased 200 shares of the business’s stock in a transaction dated Friday, August 8th. The shares were acquired at an average price of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO David A. Ricks purchased 1,632 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the transaction, the chief executive officer owned 546,601 shares in the company, valued at $352,431,926.77. This represents a 0.30% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by company insiders.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $724.73 on Monday. The company has a market capitalization of $685.93 billion, a PE ratio of 47.37, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The stock has a fifty day moving average of $734.15 and a 200-day moving average of $766.60. Eli Lilly and Company has a one year low of $623.78 and a one year high of $937.00.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.